GlycoVaxyn AG
Ditch Route 3
Streaks
8952
Tel: 41-44-733-85-85
Fax: 41-44-733-85-74
Email: welcome(at)glycovaxyn.com
16 articles about GlycoVaxyn AG
-
Polyneuron Pharmaceuticals Completes CHF3.1 Million Seed Financing
5/14/2018
Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymer treatments for autoimmune diseases, today announced the closing of a CHF3.1 million financing, following the receipt of a second tranche.
-
GlaxoSmithKline Takes Full Control of GlycoVaxyn AG for $190 Million
2/11/2015
-
GlycoVaxyn AG Announces The Initiation Of A Phase I Clinical Trial In Collaboration With Janssen Pharmaceutical Inc. For A Vaccine Against Extra-Intestinal Pathogenic Escherichia Coli Causing Urinary Tract Infection
7/1/2014
-
GlycoVaxyn AG Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine
7/29/2013
-
GlycoVaxyn AG Announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors
3/6/2013
-
GlycoVaxyn AG Signs Exclusive License Agreement and Enters Research and Development Collaboration With Janssen Pharmaceuticals, Inc., to Develop Multi-Valent Bacterial Vaccine
1/4/2013
-
GlycoVaxyn AG Announces Strategic Collaboration With GlaxoSmithKline to Develop New Bacterial Vaccines using GlycoVaxyn's Bio-Conjugation Technology
12/19/2012
-
GlycoVaxyn AG's Staphylococcus aureus Bioconjugate Vaccine Candidate Protects Mice Against Invasive S. aureus Infection
9/16/2011
-
GlycoVaxyn AG to Host Second Annual Science Day to Discuss Challenges and Opportunities in Vaccine Development
6/15/2011
-
GlycoVaxyn AG Phase I Clinical Study Shows Positive Data with Shigella Dysenteriae Vaccine Candidate
10/8/2010
-
GlycoVaxyn AG and a Harvard University Affiliated Hospital Receive USD 3.4 Million National Institutes of Health (NIH) Grant for Staphylococcus aureus Vaccine Development
5/4/2010
-
GlycoVaxyn AG's First Clinical Study with Bioconjugate Vaccine Initiated
2/23/2010
-
GlycoVaxyn AG Appoints Renowned Vaccinologist Dr Stanley Plotkin to Supervisory Board
10/6/2009
-
GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners
3/5/2009
-
GlycoVaxyn AG Appoints Philippe Dro as CEO
5/20/2008
-
GlycoVaxyn AG Completes CHF 11.5 Million Series A Financing to Advance Novel Conjugated Vaccine Pipeline Towards Clinic
7/16/2007